Putaminal serotonergic innervation

Neurology

Volumn 85, Issue 10, 2015, Pages 853-860

  Lee, Jee Young ^a   Seo, Seongho ^a   Lee, Jae Sung ^a   Kim, Han Joon ^b   Kim, Yu Kyeong ^a   Jeon, Beom S ^b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL) BENZONITRILE C 11; LEVODOPA; N (3 FLUOROPROPYL) 2 CARBOMETHOXY 3 (4 IODOPHENYL) NOTROPANE F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; DOPAMINERGIC NERVE CELL; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PET-CT SCANNER; PRIORITY JOURNAL; PUTAMEN; THALAMUS; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; COMPLICATION; DISEASE COURSE; DYSKINESIAS; METABOLISM; MIDDLE AGED; RISK FACTOR; SCINTISCANNING; SEROTONINERGIC NERVE CELL;

AGED; DISEASE PROGRESSION; DYSKINESIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RISK FACTORS; SEROTONERGIC NEURONS;

EID: 84953344162     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001909     Document Type: Article

References (39)

1. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
2. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
4. Kostic VS, Marinkovic J, Svetel M, Stefanova E, Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2002;9:9-14.
5. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 suppl 1):S2-S11.
6. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 1998;245:151-154.
7. Arai R, Karasawa N, Geffard M, Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995;195:195-198.
8. Rylander D, Parent M, O'Sullivan SS, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010;68:619-628.
9. Carta M, Carlsson T, Kirik D, Björklund A Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-1833.
10. Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dop-amine transporter ratio. Mov Disord 2011;26:1997-2003.
11. Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014;124:1340-1349.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neuro-surg Psychiatry 1992;55:181-184.
13. Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010;16:202-207.
14. Wang J, Zuo CT, Jiang YP, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007;254:185-190.
15. 11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001;21: 1342-1353.
16. Kang KW, Lee DS, Cho JH, et al. Quantification of F-18 FDG PET images in temporal lobe epilepsy patients using probabilistic brain atlas. Neuroimage 2001;14:1-6.
17. Lee JS, Lee DS. Analysis of functional brain images using population-based probabilistic atlas. Curr Med Imaging Rev 2005;1:81-87.
18. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM. Serotonergic terminal transporters are differentially affected in Parkinson's disease and progressive supranu-clear palsy: an autoradiographic study with [3H]citalo-pram. Neuroscience 1993;54:691-699.
19. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008;28:441-444.
20. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010;40:216-221.
21. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008;131:120-131.
22. Strecker K, Wegner F, Hesse S, et al. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. J Neurol 2011;258:19-26.
23. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(1)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 2006;319:1225-1234.
24. Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Dis-ord 2009;15:445-452.
25. Kannari K, Kurahashi K, Tomiyama M, et al. Tandospir-one citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease [in Japanese]. No To Shinkei 2002;54:133-137.
26. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007; 22:179-186.
27. Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neuro-surg Psychiatry 1991;54:376-377.
28. Hammerstad JP, Carter J, Nutt JG, et al. Buspirone in Parkinson's disease. Clin Neuropharmacol 1986;9:556-560.
29. Muller T, Olanow CW, Nutt J, Hicking C, Laska E, Russ H. The PADDY-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in Parkinson's disease patients. Mov Disord 2006;21:S591.
30. Rascol O, Damier P, Goetz CG, et al. A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of L-dopa-induced dyskinesia associated with Parkinson's disease: the Paddy-1 study. Mov Disord 2006;21:S492-S493.
31. Bézard E, Muñoz A, Tronci E, et al. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dys-kinesia. Neurosci Res 2013;77:242-246.
32. Bezard E, Tronci E, Pioli EY, et al. Study of the antidy-skinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013;28:1088-1096.
33. Bishop C, George JA, Buchta W, et al. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 2012;36:2839-2848.
34. Tronci E, Lisci C, Stancampiano R, et al. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dys-kinesia in the rat Parkinson's disease model. Neurobiol Dis 2013;60:108-114.
35. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131:3380-3394.
36. Ulusoy A, Sahin G, Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci USA 2010;107:13159-13164.
37. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007;30:211-219.
38. Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci 2012;19:343-348.
39. Lee JY, Seo SH, Kim YK, et al. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry 2014;85: 23-30.